Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-6552 in participants with Narcolepsy Type 1 (NT1). Part 1 will evaluate safety, to...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Merck Sharp & Dohme LLC
NCT07299097 · Narcolepsy Type 1, Narcolepsy Type 2
NCT07363720 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
NCT05816382 · Narcolepsy Type 1
NCT06767683 · Narcolepsy Type 1, Narcolepsy Type 2, and more
NCT06952699 · Narcolepsy Type 2
Delta Waves, Inc. ( Site 0008)
Colorado Springs, Colorado
Teradan Clinical Trials, LLC ( Site 0005)
Brandon, Florida
NeuroTrials Research Inc ( Site 0006)
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions